ada glp-1 Dual GLP-1/GIP receptor agonist improves glycemic management and weight loss in adults living with type 1 diabetes and obesity Pharmacokinetic & ADA Assessment of

Anyone starting a program now should understand that regulatory picture and have a conversation with their clinical provider about continuity-of-care planning if the regulatory situation changes

SUSTAIN, Semaglutide Unabated Sustainability in Treatment of T2DM

95 CI 13.4 to 11.5

In February 2020, Trulicity was approved by the US FDA for new indications for use in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or multiple cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (MACE)

10.3892/ol.2017.6653 33 HigashiY.MatsuokaH.UmeiH.SuganoR.FujiiY.SogaJ.et al (2010)

Nature (1993) 361:3625